RTW Investments LP Has $244.93 Million Stock Position in Dyne Therapeutics, Inc. (NASDAQ:DYN)

RTW Investments LP boosted its holdings in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,818,641 shares of the company’s stock after buying an additional 431,503 shares during the period. Dyne Therapeutics makes up about 3.5% of RTW Investments LP’s holdings, making the stock its 8th largest holding. RTW Investments LP owned 6.70% of Dyne Therapeutics worth $244,926,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC boosted its stake in Dyne Therapeutics by 904.1% during the second quarter. Nisa Investment Advisors LLC now owns 743 shares of the company’s stock valued at $26,000 after buying an additional 669 shares during the period. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the third quarter worth about $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics during the third quarter worth about $36,000. US Bancorp DE lifted its stake in Dyne Therapeutics by 776.9% during the third quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Values First Advisors Inc. bought a new stake in Dyne Therapeutics during the third quarter worth about $62,000. Institutional investors own 96.68% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on DYN shares. Chardan Capital reaffirmed a “buy” rating and set a $50.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, November 13th. StockNews.com lowered Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Guggenheim lifted their price target on Dyne Therapeutics from $45.00 to $50.00 and gave the stock a “buy” rating in a research note on Thursday, August 15th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and decreased their price objective for the stock from $43.00 to $35.00 in a report on Thursday, October 24th. Finally, Piper Sandler reiterated an “overweight” rating and issued a $53.00 price objective on shares of Dyne Therapeutics in a report on Monday, September 23rd. One investment analyst has rated the stock with a sell rating, one has given a hold rating, nine have given a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $50.82.

Dyne Therapeutics Price Performance

Shares of NASDAQ:DYN opened at $29.44 on Thursday. Dyne Therapeutics, Inc. has a 1 year low of $10.33 and a 1 year high of $47.45. The company has a market cap of $3.00 billion, a PE ratio of -8.27 and a beta of 1.09. The stock’s 50-day moving average is $31.45 and its 200 day moving average is $35.49.

Dyne Therapeutics (NASDAQ:DYN) last posted its earnings results on Tuesday, November 12th. The company reported ($0.96) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). Analysts expect that Dyne Therapeutics, Inc. will post -3.45 EPS for the current fiscal year.

Insider Transactions at Dyne Therapeutics

In related news, Director Carlo Incerti sold 16,500 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, Director Jason P. Rhodes sold 782 shares of the company’s stock in a transaction that occurred on Thursday, November 14th. The shares were sold at an average price of $33.10, for a total value of $25,884.20. Following the completion of the transaction, the director now directly owns 15,962 shares in the company, valued at $528,342.20. This trade represents a 4.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 176,257 shares of company stock valued at $6,193,718 in the last ninety days. 20.77% of the stock is currently owned by corporate insiders.

Dyne Therapeutics Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.